Today (March 10), A-Shares rebounded strongly. After the Shanghai and Shenzhen stock markets opened sharply higher, they maintained a high shock in the morning and narrowed their gains in the afternoon. On the disk, in terms of industry, pharmaceutical commerce, medical devices, traditional Chinese medicine, batteries, wind power, energy metals, wine making, pesticides and veterinary drugs were among the top gainers; Gold, mining and other industries made a slight correction. In terms of subject stocks, covid-19 detection, covid-19 drugs, assisted reproduction, CRO, vaccine cold chain, photovoltaic buildings, sodium ion batteries, etc. led the increase.
Contemporary Amperex Technology Co.Limited(300750) violent counterattack! The price of battery grade lithium carbonate continues to rise. Can the rebound continue
On March 10, Contemporary Amperex Technology Co.Limited(300750) opened high and walked high. On the news side, Shanghai Ganglian E-Commerce Holdings Co.Ltd(300226) data show that on March 7, the price of battery grade lithium carbonate reached 502500 yuan / ton. The average spot price of lithium hydroxide reached 459500 yuan / ton. At the beginning of this year, the price of battery grade lithium carbonate was only 300000 yuan / ton, compared with 50000 yuan / ton at the beginning of last year.
On March 9, it was reported that the price of battery grade lithium carbonate continued to rise, the cost pressure of midstream battery plants was huge, and many battery plants in China did not buy goods or receive orders to fight the soaring price of lithium carbonate. In response, Contemporary Amperex Technology Co.Limited(300750) responded that this situation did not exist in the company.
Guotai Junan Securities Co.Ltd(601211) research report said that the rapid rise in the price of lithium carbonate was mainly driven by the urgent demand for lithium carbonate from lithium iron phosphate manufacturers, especially overseas energy storage batteries. However, the supply of lithium resources cannot be increased rapidly in a short time, and the contradiction between supply and demand may exist for a long time.
In the secondary market, recently, Contemporary Amperex Technology Co.Limited(300750) share price fell continuously, with a cumulative decline of 14.61% from March 1 to March 8. At the same time, the shares were significantly reduced by northbound funds, and the northbound funds sold Pharmaron Beijing Co.Ltd(300759) 29 million yuan yesterday; On March 8, the net sales were 2.631 billion yuan; On March 7, the net sales exceeded 1.3 billion yuan.
fluorine concept stocks are active Do-Fluoride New Materials Co.Ltd(002407) strong limit company’s net profit increased nearly 25 times last year times 23456
Fluorine concept stocks had an active intraday trend on the 10th. As of press time, Guangzhou Tinci Materials Technology Co.Ltd(002709) , Do-Fluoride New Materials Co.Ltd(002407) limit, Zhejiang Yongtai Technology Co .Ltd(002326) , Lecron Industrial Development Group Co.Ltd(300343) , Zhejiang Zhongxin Fluoride Materials Co.Ltd(002915) , Zhejiang Juhua Co.Ltd(600160) , Yunnan Yuntianhua Co.Ltd(600096) , etc. rose higher. In terms of news, on the evening of March 9, Do-Fluoride New Materials Co.Ltd(002407) disclosed the performance express of 2021. During the reporting period, the company achieved a total operating revenue of 7.809 billion yuan, a year-on-year increase of 83.95%; The net profit attributable to shareholders of listed companies was 1.26 billion yuan, a year-on-year increase of 2490.8%.
The company pointed out that during the reporting period, the new material business segment of the company was in a continuous growth trend. The market demand for new material products represented by lithium hexafluorophosphate was strong, and the sales price ushered in a new high. The new production capacity is released beyond expectations, seizing the market opportunity, and the product supply is in short supply. The company has a certain amount of reserves for the raw materials of products, and some product purchase and sales agreements have corresponding linkage mechanisms for the purchase price of raw materials and the sales price of products, effectively avoiding the adverse impact of the price rise of some raw materials. At the same time, through a number of measures such as technology renewal and iteration and improving the conversion rate of raw materials, we have realized cost reduction and efficiency increase and ensured strong profitability.
In addition, the company recently said in an institutional survey that in 2021, the company has a capacity of 20000 tons of lithium hexafluorophosphate. At present, most expansion projects are progressing smoothly, which is earlier than the expected construction period. According to the company’s production expansion progress, it is expected to have a capacity of 55000 T / a by the end of this year, with a shipment of 35 Xj Electric Co.Ltd(000400) 00 T. it is planned to exceed the capacity of 100000 t / A from 2023 to 2024.
The company recently said on the interactive platform that due to the continuous strong market demand, the company’s relevant products are in short supply and the production line is running at full capacity. According to the order demand of downstream customers, it is expected to maintain the trend of full production and full sales this year.
According to the business data disclosed on 9 Guangzhou Tinci Materials Technology Co.Ltd(002709) , from January to February 2022, the industry related to new energy vehicles maintained a high momentum of development, the production and sales of the company’s main products were booming, the new production capacity climbed smoothly, the self production rate of main raw materials increased steadily, and achieved good business results. According to the preliminary accounting of the company, from January to February 2022, the company achieved an operating revenue of about 3.3 billion yuan, an increase of about 260% year-on-year; The net profit attributable to the shareholders of the listed company was about 860 million yuan, a year-on-year increase of about 470%.
China Meheco Group Co.Ltd(600056) win the agency right of Pfizer covid-19! Boost covid-19 drug concept Aba Chemicals Corporation(300261) and other multi stock trading limits
The ‘60056 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\(a) the; Covid-19 detection concept also strengthened, with the increase of “20cm” limit of Shanghai Labway Clinical Laboratory Co.Ltd(301060) , Guangzhou Wondfo Biotech Co.Ltd(300482) , ” Beijing Hotgen Biotech Co.Ltd(688068) , Jiangsu Bioperfectus Technologies Co.Ltd(688399) , an Xu biology, etc.
On the news, China Meheco Group Co.Ltd(600056) 9 day announcement, the company signed an agreement with Pfizer Inc, will be in the agreement period (2022) responsible for Pfizer Inc COVID-19 virus treatment PAXLOVID (hereinafter referred to as “products”) in the Chinese mainland market business operation. The company also said that the final use and sales of products are greatly uncertain due to factors such as epidemic prevention and control, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
On February 11 this year, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and approved the import registration of Pfizer’s product conditionally.
The data show that paxlovid is composed of two main components. Nirmatrelvir (pf-07321332) is a covid-19 virus 3CL protease inhibitor, which can destroy the subsequent RNA replication process of covid-19 virus by blocking the activity of covid-19 virus 3CL protease. Another component, ritonavir, allows nirmatrelvir to remain active in the body for a longer time and better fight the virus. It is understood that Pfizer is accelerating the improvement of production capacity to meet the medication needs of covid-19 patients.
Some analysts pointed out that clinical studies showed that among patients treated with paxlovid within 3 and 5 days after symptom onset, the hospitalization or mortality of covid-19 patients decreased by 89% and 88% respectively, and the viral load decreased by 10 times compared with the placebo group. At the same time, in vitro data showed that paxlovid was effective against Omicron variant strain. Paxlovid has been approved by about 40 countries including Britain, Germany, Japan, Singapore and China within more than 50 days since it was urgently approved in the United States on December 22 last year. The approval in China also marks that China has the first oral specific drug covid-19 in a strict sense.
Capital Securities pointed out that Pfizer expects the output of 2022q1paxlovid to be 6 million courses, the output of 2022h1 to be 30 million courses, and the annual output to be 120 million courses (performance guidance $22 billion). Considering the strong infectivity of covid-19, with the increase of approved countries and the promotion of MPP agreement, the production capacity pressure will further increase. According to the calculation of 15% – 20% of the drug production cost, the market scale of the relevant industrial chain this year is US $3.3-4.4 billion. China’s supply chain system of small molecule drug intermediates, APIs and preparations is stable and mature, and relevant enterprises are expected to generate huge profits. Recently, cdmo enterprises boten (US $681 million) and Asymchem Laboratories (Tianjin) Co.Ltd(002821) (US $481 million + RMB 2.72 billion) have disclosed that they have obtained large orders. From the details of amount, time and so on, we speculate that they are Pfizer paxlovid orders. With the gradual expansion of production capacity and product delivery, enterprises in the whole industrial chain are expected to benefit.
provinces and cities have made it clear that assisted reproduction is included in medical insurance penetration rate is expected to continue to increase (with shares)
It is reported that in response to the message of netizens suggesting “subsidizing assisted reproduction”, Sichuan Provincial Health Commission replied that it plans to learn from the practices of individual provinces and cities and actively strive to include common assisted reproductive technology projects into the scope of medical insurance reimbursement in conjunction with relevant departments.
China Galaxy Securities Co.Ltd(601881) Securities pointed out that many provinces and cities have explicitly included common assisted reproductive technology projects into the scope of medical insurance reimbursement. Recently, the Beijing Municipal Medical Insurance Bureau, the Beijing Municipal Health Commission and the Beijing Municipal Human Resources and Social Security Bureau jointly issued the notice on standardizing the adjustment of some medical service price items, standardized the adjustment of 63 medical service price items, and included 16 auxiliary reproductive items common in outpatient treatment into the category a reimbursement scope of medical insurance, including designated institutions of public and non-public medical insurance, It will be officially implemented on March 26. Recently, Hunan and Sichuan provincial health committees have made it clear on the official platform that they will gradually explore the inclusion of common assisted reproductive technology projects with mature technology, safety and reliability and controllable cost into the scope of medical insurance reimbursement.
At present, China has the same infertility rate as developed countries, but there is still a big gap in the proportion of people receiving assisted reproductive services. Statistics show that the penetration rate of assisted reproduction in China in 2018 was only 7.0%, much lower than 30.2% in the United States in the same period. In the future, with the deepening of people’s understanding of assisted reproductive technology, the increase of per capita disposable income and the liberalization of policies to encourage fertility, the penetration rate of assisted reproductive technology in China is expected to continue to increase. It is suggested to pay attention to Jinxin reproductive, a high-quality private assisted reproductive institution with technical barriers and license barriers, its acquisition progress and the performance flexibility of the gradual recovery of American business. In addition, we can pay attention to Beikang medical, a leading PGT clinical solution provider in China.
some cement enterprises issue price increase notice focus on regional leading enterprises (with shares)
Recently, cement prices in some parts of China have continued to rise. According to chinacement.com, at present, some enterprises along the Yangtze River in Anhui are still stopping kilns for maintenance, and the clinker inventory is running at a low level. At the same time, it is driven by the increase of raw material prices. Since March 9, some major enterprises along the river have been notified to increase the clinker price by about 30 yuan / ton in the fourth round. In addition, the market demand in Wuhan, Hubei Province has been recovering recently, and the delivery of some enterprises can reach about 70-80%. In order to improve profits, major manufacturers in the region plan to raise the cement price by about 20-30 yuan / ton on the 10th.
China Merchants Securities Co.Ltd(600999) pointed out that the national cement price index rose, and the cement price index rose in most regions such as the Yangtze River, North China, East China and southwest China. The rise of coal and clinker prices has driven the recent rise of cement prices to a certain extent. At the same time, the peak production or kiln shutdown for maintenance has led to the low clinker inventory. From the perspective of industry fundamentals, the performance forecast profit of sector enterprises in 2021 is mostly negative growth, which makes the cement at the bottom of the cycle and the valuation is low. In March, with the arrival of the peak construction season, the cement price is expected to enter the upward channel. It is recommended to pay attention to the sector opportunities.
Sealand Securities Co.Ltd(000750) believes that in the short term, despite the slow recovery of downstream demand at the beginning of the market, driven by the rise of the cost side, the upward trend of cement prices in various regions is obvious. It is expected that in March, with the continuous increase of downstream demand, cement prices in most regions will begin to rebound. At present, it is recommended to take the lead in the cement area Anhui Conch Cement Company Limited(600585) , Gansu Shangfeng Cement Co.Ltd(000672) , focusing on Huaxin Cement Co.Ltd(600801) , Xinjiang Tianshan Cement Co.Ltd(000877) .
2022 mid year Japan Forum on pollution reduction, carbon reduction and hydrogen energy development was held in Qiong hydrogen energy industry has huge development space
The “2022 China Japan Forum on pollution reduction, carbon reduction and hydrogen energy development” was held in Haikou on March 9, Hainan Daily reported. Shi Dinghuan, chairman of the expert committee of the energy investment committee of the China Investment Association, pointed out that the development of hydrogen energy has attracted increasing attention from all countries. Hainan Province has also formulated the “14th five year plan” for hydrogen energy development, and Japan has always been in the forefront of the world in terms of hydrogen energy development. Hainan free trade port has superior policies and business environment, which is conducive to relevant cooperation between China and Japan.
Jia Bingjun, chairman of Datang Hainan Energy Development Co., Ltd., introduced the company’s deep integration into the construction of Hainan clean energy island. It is reported that Datang Hainan Company will take “green hydrogen” as the development core and realize the application in multiple application scenarios such as transportation, energy, energy storage and power generation; Foster and promote the implementation of hydrogen energy industry projects in photovoltaic, offshore wind power hydrogen production, gas turbine waste heat hydrogen production, biomass hydrogen production, hydrogen production and hydrogenation station cooperation.
Dongguan Securities pointed out that the demand for hydrogen energy has accelerated and the development space of hydrogen energy industry is huge. In 2020, China’s hydrogen demand will be about 33.42 million tons. By 2030, China’s annual hydrogen demand will increase to 37.15 million tons, accounting for about 5% of the terminal energy consumption. By 2060, China’s annual hydrogen demand will increase to about 130 million tons, accounting for about 20% of the terminal energy consumption. China’s hydrogen demand will gradually increase in the future. As other large central enterprises enter the hydrogen energy industry, the market concentration of the hydrogen energy industry is expected to increase in the future. At present, more than one-third of central enterprises are in the layout of the whole industrial chain, including hydrogen production, hydrogen storage, hydrogenation, hydrogen use and so on. There is a huge space for the development of hydrogen energy industry.
